During the month of January, the Gilead Fund showed a 2.9% increase in value,
outperforming the S&P 500 Index by a wide margin. Data published in the Journal indicates that only
two other multi-cap growth funds increased in value during the time period.
Fund is a multi-cap growth fund that seeks to provide long-term capital appreciation. It invests in
a broad range of equity securities without limitation to market capitalization, with the majority
of its holdings falling into the mid- and small-cap range. As of February 1, 2009, the Fund has
$0.8 million in assets under management.
The advisor for the Fund is Eventide Asset Management,a Boston-based investment
advisory firm that offers no-load mutual funds for both individual and institutional investors. The
Gilead Fund, launched on July 1, 2008, is Eventide's first mutual fund.
potential investments in an attempt to ensure that the securities chosen for the Gilead Fund are of
companies that are not inconsistent with core Christian ethical values. Specifically, Eventide
seeks to avoid investing in companies that support abortion, gambling, pornography, tobacco,
alcohol, weaponry, violent video gaming, environmentally irresponsible actions, or animal cruelty.
Currently, the top three stock positions in the Fund are AMAG Pharmaceuticals, Bristow
Group, and El Paso Corp.